More on PFE

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+26.9% Growth)
- Ratings (4.1 Score)
- Holders
- Dividends (4% Yield)
- Event Driven Deals
- FDA
- FDA Archive

Financials

Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (7/28/21)
- M&A (6/30/20 *Est)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

PFE Income Statement

Click line-items for a historical chart and %
Revenues
Costs and expenses:
Cost of sales
Selling, informational and administrative expenses 3.56B
Research and development expenses 1.88B
Amortization of intangible assets
Acquisition-related in-process research and development charges
Restructuring charges and certain acquisition-related costs 531M
Other deductions--net
Income from continuing operations before provision for taxes on income 1.6B
Provision for taxes on income 284M
Income from continuing operations 1.32B
Discontinued operations:
Income from operations--net of tax
Gain on sale of discontinued operations--net of tax
Discontinued operations--net of tax 0
Net income before allocation to noncontrolling interests 1.32B
Less: Net income attributable to noncontrolling interests 0
Net income attributable to Pfizer Inc. 1.32B
Earnings per share--basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders 0.22
Discontinued operations--net of tax (in dollars per share) 0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share) 0.22
Earnings per share--diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) 0.22
Discontinued operations--net of tax (in dollars per share) 0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share) 0.21
Weighted-average shares used to calculate earnings per common share:
Basic (in shares) 6.07B
Diluted (in shares) 6.14B
Cash dividends paid per common share (in dollars per share) 0.3